CN109400679B - Blood fat reducing hexapeptide derived from spotted maigre swimming bladder and application thereof - Google Patents
Blood fat reducing hexapeptide derived from spotted maigre swimming bladder and application thereof Download PDFInfo
- Publication number
- CN109400679B CN109400679B CN201811397417.0A CN201811397417A CN109400679B CN 109400679 B CN109400679 B CN 109400679B CN 201811397417 A CN201811397417 A CN 201811397417A CN 109400679 B CN109400679 B CN 109400679B
- Authority
- CN
- China
- Prior art keywords
- hexapeptide
- blood fat
- fat reducing
- lipid
- spotted maigre
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000004369 blood Anatomy 0.000 title claims abstract description 39
- 239000008280 blood Substances 0.000 title claims abstract description 39
- 230000001603 reducing effect Effects 0.000 title claims abstract description 32
- 241000347391 Umbrina cirrosa Species 0.000 title claims abstract description 31
- 230000009182 swimming Effects 0.000 title description 8
- 210000004712 air sac Anatomy 0.000 claims abstract description 44
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 26
- 150000002632 lipids Chemical class 0.000 claims abstract description 22
- 238000007254 oxidation reaction Methods 0.000 claims abstract description 12
- 230000003647 oxidation Effects 0.000 claims abstract description 11
- 230000002293 adipogenic effect Effects 0.000 claims abstract description 8
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 7
- 239000003814 drug Substances 0.000 claims abstract description 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 6
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 claims abstract description 4
- 230000000055 hyoplipidemic effect Effects 0.000 claims description 17
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 13
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- 241000961004 Nibea albiflora Species 0.000 claims description 8
- 239000004480 active ingredient Substances 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- PHIQHXFUZVPYII-ZCFIWIBFSA-O (R)-carnitinium Chemical compound C[N+](C)(C)C[C@H](O)CC(O)=O PHIQHXFUZVPYII-ZCFIWIBFSA-O 0.000 claims description 5
- 101000755720 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) Palmitoyltransferase akr1 Proteins 0.000 claims description 5
- 229960004203 carnitine Drugs 0.000 claims description 5
- 235000012000 cholesterol Nutrition 0.000 claims description 5
- 102000023732 binding proteins Human genes 0.000 claims description 4
- 108091008324 binding proteins Proteins 0.000 claims description 4
- 230000001105 regulatory effect Effects 0.000 claims description 4
- 108010074438 Sterol Regulatory Element Binding Protein 2 Proteins 0.000 claims description 3
- 230000002222 downregulating effect Effects 0.000 claims description 3
- 230000003834 intracellular effect Effects 0.000 claims description 3
- 102000008079 Sterol Regulatory Element Binding Protein 2 Human genes 0.000 claims description 2
- 101150073133 Cpt1a gene Proteins 0.000 claims 1
- 102100026798 Peroxisomal acyl-coenzyme A oxidase 1 Human genes 0.000 claims 1
- 108010038807 Oligopeptides Proteins 0.000 abstract description 8
- 102000015636 Oligopeptides Human genes 0.000 abstract description 8
- 235000014113 dietary fatty acids Nutrition 0.000 abstract description 7
- 229930195729 fatty acid Natural products 0.000 abstract description 7
- 239000000194 fatty acid Substances 0.000 abstract description 7
- 150000004665 fatty acids Chemical class 0.000 abstract description 7
- 239000002778 food additive Substances 0.000 abstract description 6
- 235000013373 food additive Nutrition 0.000 abstract description 6
- 230000036541 health Effects 0.000 abstract description 6
- 238000011161 development Methods 0.000 abstract description 3
- 229940079593 drug Drugs 0.000 abstract 2
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 24
- 230000000694 effects Effects 0.000 description 19
- 239000000243 solution Substances 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 9
- 238000004007 reversed phase HPLC Methods 0.000 description 9
- 102000004539 Acyl-CoA Oxidase Human genes 0.000 description 8
- 108020001558 Acyl-CoA oxidase Proteins 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 241000251468 Actinopterygii Species 0.000 description 6
- 102000008186 Collagen Human genes 0.000 description 6
- 108010035532 Collagen Proteins 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- 235000019688 fish Nutrition 0.000 description 6
- 239000012086 standard solution Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 5
- 238000004255 ion exchange chromatography Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 241000237858 Gastropoda Species 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 229920001436 collagen Polymers 0.000 description 4
- 238000004440 column chromatography Methods 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 239000012154 double-distilled water Substances 0.000 description 4
- 238000010828 elution Methods 0.000 description 4
- 238000005227 gel permeation chromatography Methods 0.000 description 4
- XELZGAJCZANUQH-UHFFFAOYSA-N methyl 1-acetylthieno[3,2-c]pyrazole-5-carboxylate Chemical compound CC(=O)N1N=CC2=C1C=C(C(=O)OC)S2 XELZGAJCZANUQH-UHFFFAOYSA-N 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 238000000108 ultra-filtration Methods 0.000 description 4
- 241000480037 Argyrosomus japonicus Species 0.000 description 3
- 108091005658 Basic proteases Proteins 0.000 description 3
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 3
- 108010020396 Sterol Regulatory Element Binding Proteins Proteins 0.000 description 3
- 102000009822 Sterol Regulatory Element Binding Proteins Human genes 0.000 description 3
- 239000003524 antilipemic agent Substances 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108090001030 Lipoproteins Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 108010074436 Sterol Regulatory Element Binding Protein 1 Proteins 0.000 description 2
- 102000008078 Sterol Regulatory Element Binding Protein 1 Human genes 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 238000000265 homogenisation Methods 0.000 description 2
- 239000000413 hydrolysate Substances 0.000 description 2
- 235000004213 low-fat Nutrition 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 229910021642 ultra pure water Inorganic materials 0.000 description 2
- 239000012498 ultrapure water Substances 0.000 description 2
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000031091 Amnestic disease Diseases 0.000 description 1
- 208000032467 Aplastic anaemia Diseases 0.000 description 1
- 241000208340 Araliaceae Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- ITYRYNUZHPNCIK-GUBZILKMSA-N Glu-Ala-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(O)=O ITYRYNUZHPNCIK-GUBZILKMSA-N 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 208000019395 Lactation disease Diseases 0.000 description 1
- 208000036626 Mental retardation Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241001596951 Nibea Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 241000269821 Scombridae Species 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 102100026841 Sterol regulatory element-binding protein 2 Human genes 0.000 description 1
- 206010042576 Suppressed lactation Diseases 0.000 description 1
- DNUJCLUFRGGSDJ-YLVFBTJISA-N Trp-Gly-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CC1=CNC2=CC=CC=C21)N DNUJCLUFRGGSDJ-YLVFBTJISA-N 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000006986 amnesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000007872 degassing Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000007368 endocrine function Effects 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003520 lipogenic effect Effects 0.000 description 1
- 235000020640 mackerel Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000007830 nerve conduction Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000007430 reference method Methods 0.000 description 1
- 208000004124 rheumatic heart disease Diseases 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention provides a blood fat reducing hexapeptide derived from air bladder of spotted maigre and application thereof, belonging to the technical field of blood fat reducing oligopeptide, wherein the peptide consists of an amino acid sequence of SEQ ID NO. 1, and the molecular weight is 687.75Da in ESI-MS determination. The application of the blood fat reducing hexapeptide in preparing blood fat reducing medicines and/or health products and/or food additives. The blood fat reducing hexapeptide can lower the expression level of adipogenic genes, promote the beta oxidation of fatty acid, reduce the generation of lipid, has good blood fat reducing activity and is derived from air bladder of spotted maigre, and can be applied to the development of blood fat reducing medicines, health products and food additives.
Description
Technical Field
The invention belongs to the technical field of blood fat reducing oligopeptides, and particularly relates to a blood fat reducing hexapeptide derived from spotted maigre swim bladders and application thereof.
Background
Sea fish swim bladder is one of the "ocean eight delicacies" and is known as "ocean ginseng". The swimming bladder comprises high-grade collagen, mucopolysaccharide, vitamins, and trace elements such as calcium, zinc, ferrum, and selenium. The swim bladder can be well digested, absorbed and utilized by human body because of low fat content and the main component of the swim bladder is biomacromolecule collagen protein. It is a material that supplements the human body with synthetic proteins, as is most meats. Collagen in human body is stored in tissue and organ in the form of aqueous solution, and plays a role in improving the tissue nutrition state. Meanwhile, collagen protein can also accelerate metabolism. The food rich in collagen influences the physiological functions of tissues through the combined water of the collagen, not only can enhance the nutrition of a human body, but also can promote the growth and development of the human body, enhance the resistance of the human body and delay senility. The long history of eating swim bladders in China is recorded in the performances of the swim bladders in Beiwei 'Zimin' Shu, Tang Dynasty 'Xin Tang Shu-geographical Zhi' and Li Shizhen 'Ben Cao gang mu'. Modern pharmacology holds that: swim bladder has sweet taste and neutral nature, and has effects of nourishing blood, stopping bleeding, invigorating kidney, and arresting spontaneous emission. The fish dart can be used in combination with Chinese medicinal materials to treat peptic ulcer, pulmonary tuberculosis, rheumatic heart disease, aplastic anemia, and vasculitis. Recently, the medical workers in China also find that swim bladders can enhance the digestion and absorption functions of gastrointestinal tracts, improve appetite, and are beneficial to preventing and treating inappetence, anorexia, dyspepsia, abdominal distension, constipation and other symptoms, and can also enhance the toughness and elasticity of muscle tissues, enhance physical strength and eliminate fatigue; but also can moisten the skin, so that the skin is fine and smooth; it also has effects in improving brain, nerve and endocrine function, promoting growth and development, maintaining normal secretion of gland, preventing and treating mental retardation, slow nerve conduction, reaction retardation, infantile dysplasia, puerperal hypogalactia, senile amnesia, insomnia, etc., and improving immunity due to the fact that swim bladder contains large amount of glue solution and has effects of promoting blood circulation, replenishing blood, stopping bleeding, resisting cold, eliminating dampness, etc.
The swim bladder has the characteristics of high protein and low fat content, so the swim bladder is an excellent protein source, can supplement the protein and the essential amino acid of the human body, and has high medicinal value. At present, the application of the fish and the snail in the market is mainly cooking and dry product processing, the added value of the fish and the snail produced by dry processing is low, and the fish and the snail have obvious regionalized characteristics, mainly concentrate on coastal areas, and are rarely eaten in inland, thereby restricting the sale of swim bladders to a certain extent, and having limited economic value, so that the research of an economic and feasible deep processing technology of the fish and the snail becomes urgent affairs. At present, the technological research for preparing the blood lipid-lowering peptide from the air bladder of the spotted maigre by using an enzymolysis technology by taking the air bladder of the spotted maigre as a raw material is in a blank stage.
Disclosure of Invention
The invention aims to provide the blood fat reducing hexapeptide derived from the air bladder of spotted maigre, which can reduce the expression level of adipogenic genes, promote the beta oxidation of fatty acid, reduce the generation of lipid and has good lipid reducing activity.
The technical scheme adopted by the invention for realizing the purpose is as follows:
a blood lipid reducing hexapeptide derived from air bladder of Nibea albiflora is composed of amino acid sequence of SEQ ID NO. 1, and molecular weight is 687.75Da in ESI-MS determination. The blood fat reducing oligopeptide Trp-Gly-Ile-Glu-Ala-Leu (WGIEAL) of the air bladder of the spotted maigre can reduce the level of Triglyceride (TG) and Total Cholesterol (TC) in cells; Trp-Gly-Ile-Glu-Ala-Leu (WGIEAL) can down-regulate the expression levels of the adipogenic alcohol regulatory element binding proteins (SREBP)1c and 2, and up-regulate the expression levels of the lipid oxidation genes carnitine palmitoyl transferase-1 (CPT-1) and acyl coenzyme A oxidase (ACOX). Therefore, Trp-Gly-Ile-Glu-Ala-Leu (WGIEAL) can not only reduce the expression level of the adipogenic gene, but also promote the beta oxidation of fatty acid and reduce the generation of lipid, has good lipid-lowering activity, and can be developed into a lipid-lowering drug, a health product and a food additive.
The present invention also provides the following:
an agent for down-regulating the expression level of adipogenic genes, which comprises the hypolipidemic hexapeptide as an active ingredient, wherein the administration mode is injection administration.
A medicament for promoting the beta-oxidation of fatty acids, which comprises the above-mentioned hypolipidemic hexapeptide as an active ingredient, and is administered by injection.
An application of blood fat reducing hexapeptide derived from air bladder of Nibea albiflora in preparing blood fat reducing medicine and/or health product and/or food additive is disclosed.
A method for preparing blood lipid reducing hexapeptide from air bladder of Nibea albiflora comprises,
homogenizing air bladder of Nibea albiflora, and performing enzymolysis;
carrying out ultrafiltration and ion exchange chromatography on the obtained air bladder enzymatic hydrolysate of the spotted maigre, collecting an eluted part, and freeze-drying;
purifying the obtained ion exchange chromatography zymolyte solution by gel column chromatography and reversed phase high performance liquid chromatography to obtain the lipid-lowering hexapeptide of the mackerel swim bladder.
Preferably, the enzymolysis step of the air bladder of the spotted maigre comprises the following steps: picking fresh spotted maigre, cleaning and homogenizing, adding distilled water according to the feed-liquid ratio of 1g: 10-15 mL, adjusting the pH value to 9.0-10.0, adding alkaline protease (the enzyme activity is more than or equal to 2.0 multiplied by 10) accounting for 1.5-2.5% of the weight of the spotted maigre5U/g), enzymolysis is carried out for 4-6 h at 50-60 ℃, enzyme deactivation is carried out for 15-20 min at 95-100 ℃, cooling to room temperature, centrifugation is carried out for 20-25 min at 12,000r/min, and supernatant fluid, namely the air bladder enzymolysis fluid of the spotted maigre, is collected.
Preferably, the spotted maigre is Nibea japonica (Nibea japonica).
Preferably, the macroporous adsorbent resin column for ion exchange chromatography is D101.
Preferably, the gel column chromatography comprises the following specific steps: dissolving the ion exchange chromatography zymolyte in double distilled water to prepare a solution with the concentration of 40-50 mg/mL, centrifuging at 4 ℃ for 15-20 min at 10,000-12,000 r/min, and separating the supernatant according to the volume ratio of 1 mL: adding 20-25 mL of the extract into a Sephadex LH-20 chromatographic column, eluting with ultrapure water, and collecting an eluted component according to an absorbance curve under 215nm, wherein the component with the strongest blood fat reducing activity is gel chromatography zymolyte.
Preferably, the specific steps of RP-HPLC purification are: preparing the gel chromatography zymolyte into a solution of 50-80 mu g/mL by using double distilled water, purifying by using RP-HPLC, and screening according to the hypolipidemic activity of each component to obtain hypolipidemic hexapeptide; wherein the sample injection amount is 15-20 mu L; chromatographic column Kromasil C18(250 mm. times.4.6 mm, 5 μm); the mobile phase is 35% acetonitrile; the elution speed is 1.0-1.5 mL/min; the ultraviolet detection wavelength is 215 nm.
Compared with the prior art, the invention has the beneficial effects that:
the blood fat reducing oligopeptide Trp-Gly-Ile-Glu-Ala-Leu (WGIEAL) of the air bladder of the spotted maigre can reduce the level of Triglyceride (TG) and Total Cholesterol (TC) in cells; Trp-Gly-Ile-Glu-Ala-Leu (WGIEAL) can down-regulate the expression levels of the lipoprotein gene alcohol regulatory element binding proteins (SREBP)1c and 2, and up-regulate the expression levels of the lipid oxidation genes carnitine palmitoyl transferase-1 (CPT-1) and acyl coenzyme A oxidase (ACOX). Therefore, Trp-Gly-Ile-Glu-Ala-Leu (WGIEAL) can not only lower the expression level of the adipogenic gene, but also promote the beta oxidation of fatty acid and reduce the generation of lipid, has good lipid-lowering activity, and can be developed into a lipid-lowering drug, a health product and a food additive.
The invention adopts the technical scheme to provide the blood fat reducing hexapeptide derived from the air bladder of the spotted maigre and the application thereof, makes up for the defects of the prior art, and has reasonable design and convenient operation.
Drawings
FIG. 1 is a Sephadex LH-20 chromatogram of the macroporous resin purified fraction of example 1;
FIG. 2 is an RP-HPLC analysis of the zymolyte prepared from Sephadex LH-20 of example 1;
FIG. 3 is a mass spectrum of the hypolipidemic hexapeptide of example 1;
FIG. 4 is the effect of the hypolipidemic hexapeptide of example 1 on cell proliferation of HepG 2;
FIG. 5 is the effect of the hypolipidemic hexapeptide of example 1 on the intracellular Triglyceride (TG) content of HepG 2;
FIG. 6 is the effect of the hypolipidemic hexapeptide of example 1 on the Total Cholesterol (TC) level in HepG2 cells;
FIG. 7 is a graph showing the effect of the lipid synthesis-associated gene, sterol regulatory element-binding protein 1c (SREBP-1c), in HepG2 cells on the expression of the lipid synthesis-associated gene in example 1;
FIG. 8 is a graph showing the effect of the lipid synthesis-associated gene, sterol regulatory element-binding protein 2(SREBP-2), in HepG2 cells on the expression of the lipid synthesis-associated gene in example 1;
FIG. 9 is a graph showing the effect of the hypolipidemic hexapeptide of example 1 on the expression of carnitine palmitoyl transferase-1 (CPT-1), a gene involved in lipid oxidation in HepG2 cells;
FIG. 10 is a graph showing the effect of the hypolipidemic hexapeptide of example 1 on the expression of acyl-coenzyme A oxidase (ACOX), a gene involved in lipid synthesis in HepG2 cells.
Detailed Description
The blood lipid-lowering hexapeptide derived from air bladder of spotted maigre and the application thereof according to an embodiment of the present invention will be further described with reference to the following specific examples.
Example 1:
a blood lipid reducing hexapeptide derived from air bladder of spotted maigre comprises peptide composed of amino acid sequence of SEQ ID NO. 1, and the amino acid sequence is Trp-Gly-Ile-Glu-Ala-Leu (WGIEAL).
A method for preparing blood lipid reducing hexapeptide from air bladder of Nibea albiflora comprises,
1) enzymolysis of the air bladder of the spotted maigre: collecting fresh Nibea japonica, picking air bladder, cleaning, homogenizing, adding distilled water at a ratio of 1g to 12mL, adjusting pH to 9.5, adding alkaline protease (with enzyme activity of 2.0 × 10 or more) 2.0% of air bladder weight5U/g), carrying out enzymolysis for 5h at 55 ℃, inactivating enzyme at 95 ℃ for 15min, cooling to room temperature, centrifuging at 12000r/min for 25min, and collecting supernatant, namely the air bladder enzymolysis liquid of the spotted maigre;
2) preparing lipid-lowering oligopeptide from spotted maigre swimming bladder: and (3) classifying the enzymolysis liquid of the swimming bladder of the spotted maigre by using an ultrafiltration membrane with the cut-off molecular weight of 1kDa, and collecting the component with the cut-off molecular weight of less than 1kDa to obtain the ultrafiltration enzymolysis liquid. The ultrafiltration enzymolysis liquid is prepared by mixing the following components in a volume ratio of 1 mL: adding 8mL of the lipid-lowering hexapeptide into a macroporous adsorption resin column filled with D101, eluting by using 3 columns of volume, then eluting by using 95 ethanol with 2 columns of volume, collecting ethanol elution parts, freeze-drying, preparing a freeze-dried sample into a solution with a certain concentration, and purifying by using gel column chromatography and reversed phase high performance liquid chromatography (RP-HPLC) respectively to obtain the lipid-lowering hexapeptide of the air bladder of the spotted maigre, and determining the structure of the lipid-lowering hexapeptide by using an amino acid sequence analyzer and a mass spectrum, wherein the specific process comprises the following steps:
gel column chromatography: dissolving the ion exchange chromatography zymolyte in double distilled water to prepare a solution with the concentration of 45mg/mL, centrifuging at 4 ℃ and 12000r/min for 20min, and separating the supernatant according to the volume ratio of 1 mL: adding 20-25 mL of the extract into a Sephadex LH-20 chromatographic column, eluting with ultrapure water, and collecting an elution component NJ-II according to an absorbance curve (shown in figure 1) at 280nm to obtain a gel chromatography zymolyte;
② RP-HPLC purification: preparing the gel chromatography zymolyte NJ-II into a solution of 40-50 mu g/mL by using double distilled water, and purifying by using RP-HPLC, wherein the sample volume is 15-20 mu L; chromatographic column Kromasil C18(250 mm. times.4.6 mm, 5 μm); mobile phase: 35% acetonitrile; the elution speed is 1.0-1.5 mL/min; ultraviolet detecting wavelength is 215nm, hypolipidemic active oligopeptide (shown in figure 2) is prepared according to hypolipidemic activity, RP-HPLC detects that the oligopeptide is a single peak, a protein/polypeptide sequence analyzer is used for determining that the amino acid sequence is Trp-Gly-Ile-Glu-Ala-Leu (WGIEAL), and ESI-MS determines that the molecular weight is 687.75Da (shown in figure 3).
The activity evaluation is carried out on the prepared blood fat reducing oligopeptide Trp-Gly-Ile-Glu-Ala-Leu (WGIEAL) of the air bladder of the spotted maigre, and the result (shown in a figure 4-10) shows that: Trp-Gly-Ile-Glu-Ala-Leu (WGIEAL) can reduce intracellular Triglyceride (TG) and Total Cholesterol (TC) levels; in addition, Trp-Gly-Ile-Glu-Ala-Leu (WGIEAL) can down-regulate the expression levels of the lipoprotein gene alcohol regulatory element binding proteins (SREBP)1c and 2, and up-regulate the expression levels of the lipid oxidation genes carnitine palmitoyltransferase-1 (CPT-1) and acyl-CoA oxidase (ACOX). Therefore, Trp-Gly-Ile-Glu-Ala-Leu (WGIEAL) can not only reduce the expression level of the lipogenic gene, but also promote the beta oxidation of fatty acid and reduce the generation of lipid in the aspect of lipid-lowering mechanism, and the lipid-lowering level is greater than the lipid generation capacity, so that the lipid-lowering activity is good.
Example 2:
in order to improve the yield of the blood fat reducing hexapeptide, the optimization scheme of the preparation method of the blood fat reducing hexapeptide derived from the air bladder of spotted maigre is as follows:
the method for homogenizing the swimming bladder of the spotted maigre adopts intermittent ultrahigh-pressure homogenization, and comprises the following specific steps: homogenizing the cleaned swim bladder for 30s under the pressure of 168MPa, and then maintaining the pressure for 60 s; after the pressure is released, the same high-pressure treatment is repeated twice, namely three times of circulation. The intermittent ultrahigh pressure homogenization of the embodiment can seriously damage the integrity of swim bladder, then quickly release content substances such as protein in cells in the pressure relief process, then continuously act on a three-strand supercoiled structure with stable property of the protein under the conditions of continuous pressure increase and ultrahigh pressure to damage hydrogen bonds, further ensure that the specific space conformation of the protein is changed into a disordered loose stretching structure, a large number of hydrophobic groups originally positioned in the molecule are exposed on the surface of the molecule, the contact chance of alkaline protease and the protein in the subsequent enzymolysis process is improved, and the repeated operation is repeated, so that the yield of the blood fat reducing peptide can be maximally improved, and the energy consumption is low.
The content of free amino nitrogen in the enzymatic hydrolysates prepared in example 1 and example 2 was determined:
the free amino group determination reference method is: taking 200ml of formaldehyde, and adjusting the pH value to 8.2 by using 0.01mol/l NaOH standard solution in the process of electromagnetic stirring for later use.
Taking 5ml of solution to be tested, adding 60ml of water for degassing, adjusting the pH to 8.2 by using 0.01mol/l NaOH standard solution, keeping the pH for 1min, slowly adding 20ml of prepared formaldehyde, magnetically stirring for 3min, titrating to the pH of 9.2 by using 0.01mol/l NaOH standard solution, recording the consumption volume of NaOH, and recording the consumption volume as V1(ii) a The volume of NaOH consumed was recorded as V, using distilled water as a blank, following the above procedure2。
Free amino nitrogen content (%) calculation formula:
in the formula, c: concentration (mol/l) of NaOH standard solution;
v1: titrating the volume (ml) of NaOH standard solution consumed by the hydrolysate after adding formaldehyde to pH 9.2;
v2: the volume (ml) of NaOH standard solution consumed for titration to pH 9.2 after formaldehyde addition to the blank;
m: volume (ml) of aqueous hydrolysis solution obtained;
0.014 is the millimolar mass of nitrogen (g/mmol);
the contents of free amino nitrogen in the enzymatic hydrolysates obtained in example 1 and example 2 were respectively: 65.4% and 72.1%, which shows that the enzymolysis effect of the swimming bladder homogenate of the spotted maigre in the embodiment 2 is better than that of the embodiment 1, and the intermittent ultrahigh-pressure homogenate is adopted to improve the enzymolysis effect of the swimming bladder homogenate of the spotted maigre, so that the yield of the blood fat-reducing hexapeptide is finally improved.
Example 3:
an agent for down-regulating the expression level of adipogenic genes, comprising the above hypolipidemic hexapeptide as an active ingredient.
An agent for promoting the oxidation of fatty acid beta, comprising the above hypolipidemic hexapeptide as an active ingredient.
An application of blood fat reducing hexapeptide derived from air bladder of Nibea albiflora in preparing blood fat reducing medicine and/or health product and/or food additive is disclosed.
Effect on experimental hyperlipidemia in mice:
30 mice were taken, and the mice were divided into 3 groups of 10 mice each. After fasting for 16h, the administration group was gavaged with 2g/kg (i.e., 0.1ml/10g) of the hypolipidemic drug prepared by gavage, and the normal group and the high-fat control group were fed with 0.1 ml/per mouse of distilled water. All the animals except the normal control group were injected with 0.5ml of 75% fresh egg milk per mouse at 1 hour after the administration. After 20 hours, the eyeball blood is taken to measure the serum cholesterol, the serum cholesterol contents of the administration group, the normal group and the high fat control group are respectively 6.95mmol/L, 3.86mmol/L and 14.58mmol/L, and the blood fat reducing medicine containing the blood fat reducing hexapeptide prepared by the invention can obviously reduce the serum cholesterol content.
Conventional techniques in the above embodiments are known to those skilled in the art, and therefore, detailed descriptions thereof are omitted here.
The above embodiments are merely illustrative, and not restrictive, and those skilled in the art can make various changes and modifications without departing from the spirit and scope of the invention. Therefore, all equivalent technical solutions also belong to the scope of the present invention, and the protection scope of the present invention should be defined by the claims.
Sequence listing
<110> Zhejiang ocean university
<120> blood lipid-lowering hexapeptide derived from air bladder of spotted maigre and application thereof
<160> 1
<170> SIPOSequenceListing 1.0
<210> 2
<211> 6
<212> PRT
<213> Nibea albiflora (Nibea albiclora)
<400> 2
Trp Gly Ile Glu Ala Leu
1 5
Claims (5)
1. A blood fat reducing hexapeptide derived from air bladder of Nibea albiflora is characterized in that: peptide consisting of the amino acid sequence of SEQ ID NO. 1, having a molecular weight of 687.75Da as determined by ESI-MS.
2. An agent for down-regulating the expression levels of the adipogenic alcohol regulatory element binding proteins SREBP1c and SREBP2, comprising the hypolipidemic hexapeptide of claim 1 as an active ingredient.
3. An agent for up-regulating the expression levels of the lipid oxidation genes carnitine palmitoyl transferase-1 CPT-1 and acyl coa oxidase ACOX, comprising the lipid lowering hexapeptide of claim 1 as an active ingredient.
4. An agent for lowering intracellular triglyceride TG and total cholesterol TC levels, comprising the hypolipidemic hexapeptide of claim 1 as an active ingredient.
5. The application of the blood lipid-lowering hexapeptide derived from the air bladder of spotted maigre in the claim 1 or 2, which is characterized in that: application in preparing hypolipidemic medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811397417.0A CN109400679B (en) | 2018-11-22 | 2018-11-22 | Blood fat reducing hexapeptide derived from spotted maigre swimming bladder and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811397417.0A CN109400679B (en) | 2018-11-22 | 2018-11-22 | Blood fat reducing hexapeptide derived from spotted maigre swimming bladder and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN109400679A CN109400679A (en) | 2019-03-01 |
| CN109400679B true CN109400679B (en) | 2021-06-08 |
Family
ID=65474677
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811397417.0A Active CN109400679B (en) | 2018-11-22 | 2018-11-22 | Blood fat reducing hexapeptide derived from spotted maigre swimming bladder and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109400679B (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107602664A (en) * | 2017-10-26 | 2018-01-19 | 浙江海洋大学 | A kind of reducing blood lipid pentapeptide for coming from brown croaker air bladder and its application |
| CN108047325A (en) * | 2017-10-26 | 2018-05-18 | 浙江海洋大学 | A kind of reducing blood lipid pentapeptide for coming from the brown croaker flesh of fish and its application |
| CN108728509A (en) * | 2018-08-09 | 2018-11-02 | 浙江海洋大学 | A kind of preparation method of the fish-skin immunomodulatory peptides of Japanese croaker |
-
2018
- 2018-11-22 CN CN201811397417.0A patent/CN109400679B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107602664A (en) * | 2017-10-26 | 2018-01-19 | 浙江海洋大学 | A kind of reducing blood lipid pentapeptide for coming from brown croaker air bladder and its application |
| CN108047325A (en) * | 2017-10-26 | 2018-05-18 | 浙江海洋大学 | A kind of reducing blood lipid pentapeptide for coming from the brown croaker flesh of fish and its application |
| CN108728509A (en) * | 2018-08-09 | 2018-11-02 | 浙江海洋大学 | A kind of preparation method of the fish-skin immunomodulatory peptides of Japanese croaker |
Non-Patent Citations (1)
| Title |
|---|
| Optimization of Extraction Conditions and Characterization of Pepsin-Solubilised Collagen from Skin of Giant Croaker (Nibea japonica);Fangmiao Yu 等;《marine drugs》;20180114;第16卷(第29期);全文 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN109400679A (en) | 2019-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5996668B2 (en) | Active small molecule glue mixture, preparation method and use thereof | |
| Chen et al. | Kefir extracts suppress in vitro proliferation of estrogen-dependent human breast cancer cells but not normal mammary epithelial cells | |
| CN103230587A (en) | Composition of crocodile hemoglobin peptide and preparation method of composition | |
| CN105624247B (en) | Preparation method of Nrf2-ARE pathway activator in tuna high-F-value oligopeptide | |
| CN108047313B (en) | Chicken blood cell antioxidant peptide and fermentation preparation method thereof | |
| CN101461543A (en) | Deep-processing method of deer blood | |
| CN110590908B (en) | Micropterus-derived antibacterial peptide additive and preparation method thereof | |
| CN116042342A (en) | Ginseng juice wine and production process thereof | |
| CN111449247A (en) | Tumor patient sea cucumber peptide nutritional supplement and processing method thereof | |
| CN114032273B (en) | Multifunctional American ginseng hydrolytic peptide and preparation method and application thereof | |
| CN111876458A (en) | Urechis unicinctus antioxidant peptide and preparation and application thereof | |
| CN117965668A (en) | Bovine bone collagen peptide with antioxidant and anti-aging functions and preparation method and application thereof | |
| CN109400679B (en) | Blood fat reducing hexapeptide derived from spotted maigre swimming bladder and application thereof | |
| JP5583259B1 (en) | Novel derivative having collagen producing action and method for producing the same | |
| CN117442510A (en) | Anti-wrinkle composition based on Sirt signal channel, and preparation method and application thereof | |
| CN109180788B (en) | Preparation method and application of camel milk antioxidant polypeptide | |
| WO2021082311A1 (en) | Pea peptide having supplementary blood glucose reducing function and preparation method therefor | |
| CN114989258B (en) | Application of plant extract composition in preparing product for treating constipation and reducing weight | |
| JP5548561B2 (en) | Skin fibroblast growth promoter and skin collagen production promoter | |
| CN113854574A (en) | Novel compound bone peptide and application thereof | |
| CN114350732B (en) | Egg white protein peptide with antioxidant and anti-inflammatory effects | |
| CN105669853B (en) | Nrf2-ARE pathway activator in tuna high F value oligopeptide | |
| TWI810671B (en) | Chlorella functional extract suitable for patients with chronic kidney disease and its use | |
| CN107760745A (en) | A kind of reducing blood lipid oligopeptides of the brown croaker flesh of fish | |
| CN114836505B (en) | Small molecule anti-alcohol peptide and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20220606 Address after: 710000 No. B49, Xinda Zhongchuang space, 26th Street, block C, No. 2 Trading Plaza, South China City, international port district, Xi'an, Shaanxi Province Patentee after: Xi'an Huaqi Zhongxin Technology Development Co.,Ltd. Address before: 316000 plot C2-10, Xiaohui Industrial Zone, Putuo Zhanmao, Putuo marine science and Technology Industrial Park, Zhoushan City, Zhejiang Province Patentee before: Zhejiang Ocean University Effective date of registration: 20220606 Address after: 056800 plant 4, hi tech Incubation Park, Weixian Economic Development Zone, Handan City, Hebei Province Patentee after: Zhongkelijun Co.,Ltd. Address before: 710000 No. B49, Xinda Zhongchuang space, 26th Street, block C, No. 2 Trading Plaza, South China City, international port district, Xi'an, Shaanxi Province Patentee before: Xi'an Huaqi Zhongxin Technology Development Co.,Ltd. |